Discovery of endothelin receptor antagonists from natural products

IDrugs

Volumn 3, Issue 2, 2000, Pages 190-197

  Subbiah, Ven ^a   Katwa, Lax ^b  

^a PhytoMyco Research Corporation   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001207299     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Thomas CP, Simonson MS, Dunn MJ: Endothelin: receptors and transmembrane signals. News Physiol Sci (1992) 7:207-211.
2. Shigeno T, Mima T: A new vasoconstrictor peptide, endothelin: profiles as vasoconstrictor and neuropeptide. Cerebrovasc Brain Metab Rev (1992) 2:227-239.
3. Masaki T, Kimura S, Yanagisawa M, Goto K: Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation (1991) 84:1457-1468.
4. Rubanyi GM, Botelho LH: Endothelins. FASEB J (1991) 5:2713-2720.
5. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348:732-735.
6. Hori S, Komatsu Y, Shigemoto R, Mizuno N, Nakanishi S: Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. Endocrinology (1992) 130:1885-1895.
7. Molenaar P, O'Reilly G, Sharkey A, Kuc RE, Harding DP, Plumpton C, Gresham GA, Devenport AP: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res (1993) 72:526-538.
8. Katwa LC, Guarda E, Weber KT: Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res (1993) 27:2125-2129.
9. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730-732.
10. B receptor and identification of signal peptidase and metal proteinase cleavage sites. J Biol Chem (1991) 266:23433-23437.
11. Adachi M, Yang YY, Furuichi Y, Miyamoto C: Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem Biophys Res Commun (1991) 180:1265-1272.
12. Elshourbagy NA, Lee JA, Korman DR, Nuthalaganti P, Sylvester DR, Dilella AG, Sutiphong JA, Kumar CS: Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. Mol Pharmacol (1992) 41:465-473.
13. Simonson MS, Dunn MJ: Cellular signaling by peptides of the endothelin gene family. FASEB J (1990) 4:2989-3000.
14. Yanagisawa M, Kurihara H, Kimura S: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1989) 322:411-415.
15. Brookes DP, Jorkasky DK, Freed MI, Ohlstein EH: Pathophysiological role of endothelin and potential therapeutic targets for receptor antagonists, in Endothelin: molecular biology, physiology and pathology. Humana press Inc, Totowa, NJ (1998) 223-268.
16. Benigni A, Remuzzi G: Endothelin antagonists. Lancet (1999) 353:133-138.
17. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M: Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci (1998) 19:5-8.
18. Miyauchi T, Goto K: Heart failure and endothelin antagonists. Trends Pharmacol Sci (1999) 20:210-217.
19. Roux S, Breu V, Ertel SI, Clozel M: Endothelin antagonism with bosentan: a review of potential applications. J Molecular Med (1999) 77:364-376.
20. Cai L, Wang GJ, Mukherjee K, Xu ZL, Khalil M, Cherian MG, Chakrabarti S: Endothelins and their receptors in cirrhotic and neoplastic livers of Canadian and Chinese populations. Anticancer Res (1999) 19:2243-2248.
21. Padol I, Huang JQ, Hunt RH: Anti-ulcerogenic properties of endothelin receptor antagonists in the rat. Aliment Pharmacol Ther (1999) 13:537-544.
22. Masaki T: Endothelins: Homeostatic and compensatory actions in the circulatory and endocrine systems. Endocr Rev (1993) 14:256-268.
23. McKay KO, Armour CL, Black JL: Endothelin receptors and activity differ in human, dog, and rabbit lung. Am J Physiol (1996) 270:L37-L43.
24. Wang Y, Simonson MS, Poussegur J, Dunn MJ: Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. Biochem J (1992) 287:589-594.
25. Sawada T, Haneda M, Togawa M, Kikkawa R: Studies on type IV collagen production in culture mesangial cells. Jpn J Nephrol (1996) 38:469-474.
26. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, Yabana H, Goto K, Sugishita Y, Murata S: Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation (1999) 99:2171-2176.
27. Forbes JM, Leaker B, Hewitson TD, Becker GJ, Jones CL: Macrophage and myofibroblast involvement in ischemic acute renal failure is attenuated by endothelin receptor antagonists. Kidney Int (1999) 55:198-208.
28. Douglas SA: Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci (1997) 18:408-412.
29. Turner AJ, Barnes K, Schweizer A, Valdenaire O: Isoforms of endothelin-converting enzyme: why and where? Trends Pharmacol Sci (1998) 19:483-486.
30. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M: Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure. Circulation (1999) 99:570-577.
31. Lam YKT, Willims DL, Sigmund JM, Sawchez M, Genilloud O, Koug YL, Stevens-Miles S, Huang L, Garrity GM: Cochinmicins, novel and potent cyclodepsipeptide endothelin antagonists from a Microbispora sp. J Antibiot (1992) 45:1709-1716.
32. Zink D, Hensens OD, Iam YKT, Reamer R, Liesch JM: Cochinmicins, novel and potent cyclodepsipeptide endothelin antagonists from a Microspora sp. J Antibiot (1992) 45:1717-1722.
33. Kojiri K, Ihara M, Nakajima S, Kawamura K, Funaishi K, Yano M, Suda H: Endothelin-binding inhibitors, BE-18257a and BE-18257B. I. Taxonomy, fermentation, isolation and characterization. J Antibiot (1991) 44:1342-1347.
34. Verdine, GL: The combinatorial chemistry of nature. Nature (1996) 384:11-13.
35. Moore, M: Attack as the best form of defense: Natural product in the forefront of contemporary drug research. J Biomol Screen (1996) 1:19-23.
36. Petsko GA: For medical purposes. Nature (1996) 384:7-9.
37. Strobel GA, Long DM: Endophytic microbes embody pharmaceutical potential. ASM News (1998) 64:263-268.
38. Cragg GM: Paclitaxol (Taxol): a success story with valuable lessons for natural product drug discovery and development. Med Res Rev (1998) 18:315-331.
39. Stahelin HF: History of Cyclosporin A (Sandimmune) revisited. Experientia (1996) 52:5-13.
40. Penalva MA, Rowlands RT, Turner G: The optimization of penicillin biosynthesis in fungi. Trends Biotechnol (1998) 16:483-489.
41. Pipersberg W: Pathway engineering in secondary meatbolite-producing actinomycetes. Crit Rev Biotechnol (1994) 14:251-285.
42. Smit E, Leeflang P, Glandorf B, van Elsas JD, Wemars K: Analysis of fungal diversity in the wheat rhizosphere by sequencing of cloned PCR-amplified genes encoding 18S rRNA and temperature gradient gel electrophoresis. Appl Environ Microbiol (1999) 65:2614-2621.
43. Hebert LA, Falkenhain ME, Nahman Jr NS, Cosio FG, O'Dorisio TM: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol (1999) 19:1-6.
44. Kimura A, Ohmichi M, Takeda T, Kurachi H, Ikegami H, Koike K, Masuhara K, Hayakawa J, Kanzaki T, Kobayashi M, Akabane M, Inoue M, Miyake A, Murata Y: Mitogen-activated protein kinase cascade is involved in endothelin-1-induced rat puerperal uterine contraction. Endocrinology (1999) 140:722-731.
45. Illing B, Horn M, Han H, Hahn S, Bureik P, Ertl G, Neubauer S: Protective effect of the specific endothelin-1 antagonist BQ610 on mechanical function and energy metabolism during ischemia/reperfusion injury in isolated perfused rat hearts. J Cardiovasc Pharmacol (1996) 27:487-494.
46. Haleen S, Schroeder R, Walker D, Quenby-Brown E, Welch K, Hallak H, Uprichard A, Keiser J: Efficacy of CI-020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension. J Cardiovasc Pharmacol (1998) 31:S331-S335.
47. A antagonist CI-1020 Inhibits hypoxic pulmonary vasoconstriction in small isolated rat pulmonary arteries. Pulm Pharmacol Ther (1998) 11:177-181.
48. A receptor antagonist, determined for human endothelin receptors. J Cardiovasc Pharmacol (1995) 26:8362-3364.
49. A antagonist (A-216546). J Med Chem (1998) 41:3261-3275.
50. A receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo. Cardiovasc Res (1998), 37:765-771.
51. Wanebo JE, Arthur AS, Louis HG, West K, Kassell NF, Lee KS, Helm GA: Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Neurosurgery (1998) 43:1409-1417.
52. A receptor blockade attenuates cardiac hypertrophy independent of blood pressure effects in renovascular hypertensive rats. Hypertension (1999) 33:954-960.
53. Sato S, Yonetani Y, Fujimoto M, Kita K, Kubo K, Nakashima T: Effects of an endothelin ET(A)-receptor antagonist, S-0139, on cerebral vasospasm and behavioral changes in dogs intracisternally administered endothelin-1. Life Sci (1998) 62:191-197.
54. A receptor. Eur J Pharmacol (1999) 366:189-201.
55. A selective antagonist. Bioorg Med Chem Lett (1998) 8:1771-1776.
56. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M: Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther (1997) 283:1110-1118.
57. Brooks DP, DePalma PD, Pullen M, Elliott JD, Ohlstein EH, Nambi P: SB 234551, a novel endothelin-A receptor antagonist, unmasks endothelin-induced renal vasodilatation in the dog. J Cardiovasc Pharmacol (1998) 31:5339-8341.
58. Bialecki RA, Stinson-Fisher C, Murdoch W, Bertelsen D, Desiato M, Rumsey W: A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat. Chest (1998) 114:91S.
59. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S: Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J Pharmacol Exp Ther (1998) 286:643-649.
60. Cahill PA, Hou MC, Hendrickson R, Wang YN, Zhang S, Redmond EM, Sitzman JV: Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics. Hepatology (1998) 28:396-403.
61. B affinity. Bioorg Med Chem Lett (1998) 8:2241-2246.
62. Shibata K, Suzawa T, Ohno T, Yamada K, Tanaka T, Tsukuda E, Matsuda Y, Yamasaki M: Hybrid peptides constructed from RES-701-1, an endothelin B receptor antagonist, and endothelin; binding selectivity for endothelin receptors and their pharmacological activity. Bioorg Med Chem (1998) 6:2459-2467.
63. Koyama Y, Takemura M, Fujiki K, Ishikawa N, Shigenaga Y, Baba A: BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia (1999) 26:268-271.
64. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M: Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension (1999) 33:759-765.
65. Ogawa K, Nakamura M, Yaginuma S, Yamamoto S, Furihata K, Shin-Ya K, Seta H: Stachybocins, novel endothelin receptor antagonists, produced by Stachybotrys sp. M6222.II. Structure determination and stachybocins A, B and C. J Antibiot (1995) 48:1396-1400.
66. B receptor antagonist Ro 46-8443. FEBS Letters (1996) 383:42-45.
67. Schroeder RL, Keiser JA, Cheng XM, Haleen SJ: PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat. J Cardiovasc Pharmacol (1998) 32:935-943.
68. Dobrowolski L, Endlich K, Sadowski J, Steinhausen M: Cardiovascular and renal effects of endothelin receptor blockade with PD 145065 and interaction with urodilatin. Acta Physiol Scand (1997) 159:7-13.
69. Geshi E, Nomizo A, Arata Y, Nakatani M, Katagiri T: Effect of non-selective endothelin blockade, TAK-044, on the ischemic cellular injury of rat heart. Basic Res Cardiol (1999) 94:94-101.
70. Cody WL, He JX, Reily MD, Haleen SJ, Walker DM, Reyner EL, Stewart BH, Doherty AM: Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties. J Med Chem (1997) 40:2228-2240.
71. Hvaal K, Mathisen SR, Svindland A, Nordsletten L, Skjeldal S: Protective effect of the endothelin antagonist bosentan against ischemic skeletal muscle necrosis. Acta Orthop Scand (1999) 70:293-297.
72. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P, Roux S: Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther (1999) 290:840-846.
73. Shennib H, Lee AG, Kuang JQ, Yanagisawa M, Ohlstein EH, Giaid A: Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am J Respir Crit Care Med (1998), 157:1975-1981.
74. Chandra S, Clark LV, Coatney RW, Phan L, Sarkar SK, Ohlstein EH: Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointime formation. Circulation (1998) 97:2252-2258.
75. Williams Jr DL, Murphy KL, Nolan NA, O'Brien JA, Pittibone DJ, Kivlighn SD, Krause SM, Lis Jr EV, Zingaro GJ, Gabei RA, Clayton FC, Siegl PKS, Zhang K, Naue J, Vyas K, Walsh TF, Fitch KJ, Chakravarty PK, Greenlee WJ, Clineschmidt BV: Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther (1995) 275:1518-1526.
76. Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E: The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J Am Soc Nephrol (1999) 10:387-391.
77. Chin MH, Cioffi CL, Garay M, Neale RF, Shetty SS, DelGrande D, Mugrage B, Sills MA, Lipson KE: The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions. J Pharmacol Exp Ther (1996) 276:74-83.
78. Raschack M, Gock S, Unger L, Hahn A, Amberg W, Jansen R, Alken P, Weber A, Hergenroder S: LU302872 and its racemate (LU224332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. J Cardiovasc Pharmacol (1998) 31:5241-244.
79. B endothelin receptor antagonist. J Pharmacol Exp Ther (1999) 289:1262-1270.
80. Yoshimura S, Tsurumi Y, Takase S, Okuhara M: WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. II. Structure elucidation of WS75624 A and B. J Antibiot (1995) 48:1073-1075.
81. Kwan AL, Bavbek M, Jeng AY, Maniara W, Toyoda T, Lappe RW, Kassell NF, Lee KS: Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg (1997) 87:281-286.
82. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, Haleen SJ, Kaw S, Emoto N, Yanagisawa M: Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun (1998) 243:184-190.
83. Takaishi S, Tuchiya N, Sato A, Negishi T, Takamatsu Y, Malsushita Y, Watanabe T, Iijima Y, Haruyama H, Kinoshita T, Tanaka M, Kodama K.: B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J Antibiot (1998) 51:805-815.
84. Matsumaru K, Kashimura H, Hassan M, Nakahara A, Goto K, Fukutomi H, Muto H, Tanaka N: Phosphoramidon, an inhibitor of endothelin-converting enzyme, prevents indomethacin-induced gastric mucosal damage in rats. Life Sci (1998) 62:PL79-84.
85. Ogawa T, Ando K, Tanaka T, Uosaki Y, Matsuda Y: RES-1149-1 and 2, novel non-peptidic type B receptor produced by Aspergillus sp. I. Taxonomy of producing strain, fermentation, isolation and physico-chemical and biological properties. J Antibiot (1996) 49:1-5.
86. Yamasaki M, Yano K, Yoshida M, Matsuda Y, Yamaguchi K: RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. II. Determination of the primary sequence. J Antibiot (1994) 47:276-280.
87. Morishita Y, Chiba S, Tsukuda E, Tanaka T, Ogawa T, Yamasaki M, Yoshida M, Kawamoto I, Matsuda Y: RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. I. Characterization of producing strain, fermentation, isolation, physico-chemical and biological properties. J Antibiot (1994) 47:269-275.
88. Hayes MA, Wrigley SK, Chetland I, Reynolds EE, Ainsworth AM, Renno DV, Latif MA, Cheng XM, Hupe DJ, Charlton P, Doherty AM: Novel drimane sesquiterpene esters from Aspergillus ustus var. pseudodeflectus with endothelin receptor binding activity. J Antibiot (1996) 49:505-512.
89. Uosaki Y, Yoshida M, Ogawa T, Saitoh Y: RES-1149-1 and -2, novel non-peptidic endothelin type B receptor antagonists produced by Aspergillus sp. II. Structure determination and derivatization. J Antibiot (1996) 49:6-12.
90. Ohashi H, Akiyama H, Nishikori K, Mochizuki J: Asterric acid, a new endothelin binding inhibitor. J Antibiot (1992) 45:1684-1685.
91. Roggo BE, Hug P, Moss S, stampfli A, Kriemler HP, Pater HH: Novel spirodihydrobenzofuranlactams as antagonists of endothelin and as inhibitors of HIV-1 protease produced by Stachybotrys sp. II. Structure determination. J Antibiot (1996) 49:374-379.
92. Pairet L, Wrigley SK, Chetland I, Reynolds EE, Hayes MA, Holloway J, Ainsworth AM, Katzer W, Cheng XM, Hupe DJ: Azphilones with endothelin receptor binding activity produced by Penicillium sclerotiorum: Taxonomy, fermentation, structure elucidation and biological activity. J Antibiot (1995) 48:913-923.
93. Ogawa T, Ando K, Aotani Y, Shinoda K, Tanaka T, Tsukuda E, Yishida M, Matsuda Y: RES-1214-1 and -2, novel non-peptidic endothelin type A receptor antagonists produced by Pestalotiopsis sp. J Antibiot (1995) 48:1401-1406.
94. Jackson M, Burres NS, Karwowski JP, Alder LA, Humphrey PE, Kohl WL, McAlpine JB: Aselacins, novel compounds that inhibit binding of endothelin to its receptor. I. The producing organism, fermentation and biological activity. J Antibiot (1994) 47:523-527.
95. Hochlowski JF Hill P, Whittem DN, Scherr MH, Rasmussen RR, Dorwin SA, McAlpine JB: Aselacins, novel compounds that inhibit binding of endothelin to its receptor. I. Isolation and elucidation of structures. J Antibiot (1994) 47:528-535.
96. Tsurumi Y, Ohhata N, Iwamoto T, Shigematsu K, Nishikawa M, Kiyoto S, Okuhara M: WS79089A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (1994) 47:619-630.
97. Tsurumi Y, Ueda H, Hayashi K, Takase S, Nishikawa M, Kiyoto S, Okuhara M: WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (1995) 48:1066-1072.
98. Sakurawa K, Yasuda F, Tozyo T, Nakamura M, Sato T, Kikuchi J, Terui Y, Ikenishi Y, Iwata T, Takahashi K, Konoike T, Mihara S, Fujimoto M: Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera and structure activity relationships of its derivatives. Chem Pharm Bull (1996) 44:343-351.
99. Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Tomcowicz B, Breen A, Johnson RK: Daleformis, a new phytoalexin from the roots of Dalea filiciformis: an inhibitor of endothelin converting enzyme. J Nat Products (1997) 60:306-308.
100. Gulavita NK, Wright AE, McCarthy PJ, Pomponi SA, Kelly-Borges M, Chin M, Sills MA: Isolation and structure elucidation of 3,4-sulfatobastadin 13, an inhibitor of the endothelin A receptor, from a sponge of the genus Ianthella. J Nat Products (1993) 56:1613-1617.
101. Patil AD, Freyer AJ, Breen A, Carte B, Johnson RK: Halistanol disulfate B, a novel sulfated sterol from the sponge Pachastrelaa sp: inhibitor of endothelin converting enzyme. J Nat Products (1996) 59:606-608.
102. Tsuchiya N, Sato A, Haruyama H, Watanabe T, Iijima Y: Nahocols and isonahocols, endothelin antagonists from the brown alga, Sargassum automnale. Phytochemistry (1998) 48:1003-1011.